<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928213</url>
  </required_header>
  <id_info>
    <org_study_id>972-07-024</org_study_id>
    <nct_id>NCT00928213</nct_id>
  </id_info>
  <brief_title>PP13 and Doppler Study to Predict Preeclampsia</brief_title>
  <official_title>Combined Sonographic Examination and Placenta Protein 13 (PP13) to Compare the Risk for Development of Preeclampsia Among Among Pregnant Women With and Without a History of Preterm Delivery and Those Treated by Progesterone or Clexane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ben-Gurion University of the Negev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diagnostic Technologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Perkin Elmer Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ben-Gurion University of the Negev</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of biochemical and sonographic marker to predict the risk for developing
      preeclampsia Among biochemical markers are serum level of Placental Protein 13 (PP13) and
      Placenta Growth factor (PIGF). For sonographic marker Doppler pulsatility Index of the blood
      flow through the uterine maternal arteries is assessed.

      PP13 is produced by the placenta and released to the maternal blood circulation. It has been
      shown to be an effective serum marker for early onset preeclampsia (Nicolaides KH et al.,
      2005). The purpose of this study is to combined the assessment of the biochemical markers
      with Doppler in the first and the second trimester to provide a comprehensive evaluation of
      various methods for sequential and combined analysis to assess the risk for developing
      preeclampsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study enrolling all comers who attend the prenatal clinic
      for first trimester assessment of the risk for Down syndrome. All women are providing medical
      and obstetric history, demography and blood samples along with Doppler pulsatility Index
      during the first and the second trimester at GA 10-13 weeks and 21-23 weeks. When possible -
      blood will be drawn at hospital admission for delivery. Measurements of sonography and serum
      markers are done blinded to pregnancy outcome.

      Patients will be assigned to three groups:

        1. All comers attending the prenatal testing at GA 10-13.

        2. Patients with a history of at least 2 pregnancy loss or preterm delivery and treated
           with low molecular weight heparin at 40-80 mg/day from admission to until 12 weeks after
           delivery.

        3. Patients who admitted the emergency ObGyn clinic for bleeding during the first trimester
           and are treated with progesterone.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preeclampsia (hypertension &gt;140/90, proteinuria &gt;2+ or 300 mg/Dl in 24 hr collection</measure>
    <time_frame>pregnancy week &gt;20 till 41 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intra uterine growth restriction, preterm delivery, spontaneous abortion and Intra uterine fetal death</measure>
    <time_frame>fron conception to until a week after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control not treated, no placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient treated with low molecular weight heparin after repeated pregnancy loss</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient super from first trimester bleeding treated with progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>40 units daily admission</description>
    <arm_group_label>3</arm_group_label>
    <other_name>C-21 steroid hormone</other_name>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight Heparin</intervention_name>
    <description>40-80 mg/day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>clexan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Drug</intervention_name>
    <description>no treatment</description>
    <arm_group_label>1</arm_group_label>
    <other_name>No treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 16-45 with viable pregnancy as defined by CRL and after signing on an
             informed consent

          -  In group 1 all patients meeting the above are eligible when GA is below 14 weeks

          -  In grop 2 all patients

        Exclusion Criteria:

          -  Gestation age at enrolment &gt; 13 weeks and 6 days by LMP verified by ultrasound at
             blood taking

          -  Mental retardation or other mental disorders that impose doubts regarding the
             patient's true willingness to participate in the Study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reli Hershkovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reli Hershkovitz, MD</last_name>
    <phone>972-8-6403070</phone>
    <email>ralika@bgu.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vered Kivity, PhD, MBA</last_name>
    <phone>972-4-9937722</phone>
    <phone_ext>0</phone_ext>
    <email>vered.kivity@pregesys.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soroka Medical Center, Ben Gurion University</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reli Hershkovitz, MD</last_name>
      <phone>972-8-86403070</phone>
      <email>ralikah@bgu.ac.il</email>
    </contact>
    <contact_backup>
      <last_name>Vered Kivity, PhD, MBA</last_name>
      <phone>972-4-9937722</phone>
      <email>vered.kivity@pregenesys.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reli Hershkovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.bgu.ac.il</url>
    <description>The website of Ben Gurion University</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>June 24, 2009</last_update_submitted>
  <last_update_submitted_qc>June 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Reli Hershkovitz</name_title>
    <organization>Soroka Medical Center Ben Gurion University</organization>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>IUGR</keyword>
  <keyword>GH</keyword>
  <keyword>PP13</keyword>
  <keyword>Doppler</keyword>
  <keyword>placenta</keyword>
  <keyword>PTD</keyword>
  <keyword>Preterm delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

